By Guest Blogger Sarah Milberg, Co-Chair of the Alliance for Childhood Cancer and Director of Government Relations and Advocacy for the St. Baldrick’s Foundation Thanks to
Survivorship Matters Blog By CAC2 Individual Member Mary Beth Collins “Your child has to be alive to experience side effects” It is heard by every
By CAC2 Individual Member Joe Baber Because of my grandson, Conor, a neuroblastoma survivor, I have met so many people in our childhood cancer community
This month, Dr. Gregory Reaman was named by the Childhood Cancer Data Initiative (CCDI) as the new Scientific Director. In this role, Dr. Reaman will
Blogged with permission and thanks by the ACCELERATE Fit for Filing Working Group The ACCELERATE PLATFORM’S Fit for Filing (FFF) group was formed in 2019 to explore
The U.S. Food and Drug Administration issued a draft guidance that, when finalized, will provide the agency’s perspective on the ethical considerations for including and
Children, adolescents, and young adults (AYAs) with newly diagnosed rare tumors are now eligible to enroll in the CCDI Molecular Characterization Initiative. Rare tumors are
The Molecular Targets Platform is an NCI-supported instance of the Open Targets Platform with a focus on preclinical pediatric oncology data. It is a tool
Update from our colleagues at the Alliance for Childhood Cancer (July 28, 2022): The Senate Appropriations Committee included language to fund the Childhood Cancer STAR
Survivorship Matters Blog By CAC2 Member Mary Beth Collins, PREP4Gold During his teens, my neuroblastoma survivor Joshua was struggling in every way a person could
